Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v16-FR Version v12-FR
Language French French
Date Updated 2022-08-19 2022-07-13
Drug Identification Number 00617288 00617288
Brand name MORPHINE HP 50 - 50MG/ML USP MORPHINE HP 50 - 50MG/ML USP
Common or Proper name MORPHINE PH 50 - 50MG/ML USP MORPHINE PH 50 - 50MG/ML USP
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients MORPHINE SULFATE MORPHINE SULFATE
Strength(s) 50MG 50MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size 50ML 1LIVI CA 50ML 1LIVI CA
ATC code N02AA N02AA
ATC description OPIOIDS OPIOIDS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2021-07-23 2021-07-23
Estimated end date 2022-08-26 2022-08-12
Actual end date 2022-08-18
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments